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Given ongoing governmental cost constraints, CDC, like all government agencies, must continually 
reassess how to best expend limited resources for maximal benefit.  This is particularly true in the 
struggle to prevent and control antibiotic resistance.  On December 6 and 7, 2011, CDC convened an 
invited panel of internationally recognized experts in clinical medicine, veterinary medicine, 
microbiology, public health and health policy to provide a diverse set of opinions regarding current and 
proposed national and international public health efforts for reducing the disease burden of infections 
caused by antimicrobial resistant microorganisms.  Documents describing the charge to the expert 
consultants and the structure and function of the workshop can be found in Appendix 1.  A list of 
participants, both invited consultants and CDC staff can be found in Appendix 2.   During a series of 
breakout group discussions, consultants were asked to provide their individual assessment of the 
relative priority of a list of CDC activities drawn from the document A Public Health Action Plan to 
Combat Antimicrobial Resistance. (See Appendix 3 for an overview of the results of this process.)  In 
addition, consultants were asked to suggest additional activities to add to those already listed. (See 




A variety of methods were used to obtain feedback and input from the consultants.  A review of notes 
from all the discussions which took place during the meeting, the written feedback from the consultants 
and the results of the breakout groups’ discussions identified five general areas that fulfilled the criteria 
for strategic priorities as outlined in the charge to the consultants.  These were:   
 Domestic and international surveillance for antimicrobial resistant (AR) pathogens  
 Public-private collaboration at the state and local level for preventing the spread of AR pathogens 
 Activities to better monitor antimicrobial use and to continue to optimize antimicrobial prescribing 
in all healthcare settings 
 Promoting the development of new technologies for more rapid diagnostic testing for antimicrobial 
resistance, especially in clinical specimens  
 More precise assessments of the disease burden (especially morbidity, mortality and economic cost) 
attributable to AR infections 
For each of these priorities, the consultants made a variety of recommendations for CDC to consider. 
Domestic and international surveillance for AR pathogens  
1. Early detection of new and emerging resistance:  A priority should be ensuring early detection and 
notification of public health authorities and clinicians of the development and spread of new 
resistance patterns and new mechanisms of resistance. 
2. Overall national and regional monitoring of the scope and magnitude of antimicrobial resistance:  
CDC should publish a national annual report detailing the “State of Antimicrobial Resistance” in the 
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U.S., encompassing the most significant aspects of the national AR problem and including state-level 
breakdowns (as available) of notable resistance problems. 
3. Clinical and public health laboratory capacity building: There is tremendous variability in the 
capacity of both clinical and public health laboratories to reliably detect and identify AR both for 
clinical and PH surveillance purposes.  More detailed assessments of current capacity, needs, gaps 
and opportunities for improvement should be undertaken.  Where capacities need to be enhanced, 
CDC should work with partners to identify and promote approaches to help accomplish such 
enhancements.   
4. Enhance interoperability:  The six principal CDC surveillance systems which provide data on 
antimicrobial resistance were developed for different purposes, use different data collection 
methods and sources, have different denominators for calculating rates and do not uniformly use 
consistent definitions of what constitutes a resistant microorganism.  This is an unavoidable 
consequence of the clinical (as opposed to microbiological) origins of the surveillance models used 
for each system.  However, this lack of interoperability limits the ability to use these systems to 
provide high-level estimates of disease burden attributable to resistance and to identify populations 
at high-risk for resistant infections across more than one surveillance category (e.g., foodborne 
disease, healthcare-associated disease, vaccine-preventable disease).   Thus, it would be useful to 
implement strategies to increase interoperability of data from these systems, including statistical 
modeling, to complement current analyses with estimates of the impact of disease caused by 
antimicrobial resistance.    
5. Standard definitions:  For some bacteria, binary definitions of what constitutes resistance for public 
health surveillance purposes are clear and unambiguous (e.g., MRSA, CRE).  For others, such as P. 
aeruginosa, Acinetobacter spp., and S.. pneumoniae, the categorization of a particular 
microorganism as resistant or susceptible is subject to interpretation.  As for other public health 
events, unambiguous surveillance case definitions (which may not be identical to clinical case 
definitions) may have value for public health purposes.  Thus, developing uniform definitions for all 
microorganisms of public health significance should be explored.   
6. Syndrome antibiograms:  Models which combine data on the probability of particular microbial 
etiologies of specific syndromes in defined populations (e.g., pneumonia in nursing home patients in 
one region) with the likelihood of microorganisms being resistant to standard therapies are 
sometimes called syndrome antibiograms.  It could be useful to conduct a formal evaluation of this 
tool using surveillance data to assess its utility for enhancing empiric antimicrobial therapy and 
improving patient outcomes.   
7. Improved timeliness:  CDC surveillance data on AR, including both raw data as well as analyses and 
interpretations, should be available to public health officials and clinicians in as close to real-time as 
possible. 
8. Better communication:  CDC surveillance data on AR should be more clearly and widely 
disseminated so as to improve understanding and awareness of the scope of the problem 
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9. Availability of raw data: CDC surveillance data on AR should be available in raw form for analysis and 
inquiry online so as to improve opportunities for use of the data for both clinical and public health 
decision-making. 
10. International surveillance:  The factors described above for domestic (U.S.) surveillance all have 
parallels relating to AR as an international threat and global phenomenon.  CDC should work with 
ministries of health and international health organizations to address gaps in international 
surveillance capacity, with particular attention to:  
 Capacity building 
 Timeliness of reporting (creating an “early warning system”) 
 Establishing communication channels to ensure information sharing   
Public-private collaboration at the state and local level for preventing the spread of AR pathogens 
The transmission of resistant bacterial strains in any geographic area is the result of a complex set of 
interactions: 
 Among people in the community (non-healthcare settings), especially children and students in 
day care and schools,  
 Between people and the environment, including food products, and 
 As a result of the movement of patients across multiple healthcare settings (outpatient, 
including emergency rooms, clinics, dialysis centers, ambulatory surgery, etc., and inpatient, 
including acute care, long-term care, long-term acute care, etc.) 
 
Thus, prevention efforts need to be coordinated to ensure that interventions are maximally effective 
(and cost-effective).  The movement of persons among institutional settings can result in the 
persistence, reintroduction and/or amplification of resistance problems despite optimal efforts in a 
particular setting.   For example, reservoirs of resistant pathogens in non-acute healthcare settings may 
reintroduce resistance into acute care hospitals despite stringent efforts in the hospital to control 
emergence and spread.   
 
Such coordination needs to occur through collaboration between public health authorities, clinical 
providers and relevant community resources (schools and day-care providers, large employers, etc.)  
This will require:  
 
1. Increased clinical and public health laboratory capacity and regular reporting, either directly to 
public health authorities or other mechanisms, such as health information exchanges (see discussion 
above regarding surveillance). 
2. Increased infection control capacity in all settings:  Guidelines for preventing the spread (and 
treatment) of antimicrobial resistant pathogens and for optimal antimicrobial use are not followed 
in some instances because of a lack of awareness of what those guidelines are and/or how to 
implement them.  Through public-private partnerships, all healthcare settings, including long-term 
care and outpatient environments, should have access to expert guidance on prevention and control 
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of AR infections and optimal antimicrobial use.  CDC should work with public health authorities to 
develop capacity for sharing such expertise locally among facilities and settings.   
3. Increased surveillance capacity: as discussed above under surveillance, local and state health 
departments need to have the capacity to provide information to clinicians and infection control 
experts in all settings on current risks and threats from AR pathogens in the community.  This 
information should be made available in interpretable form to schools and other settings where 
potential transmission outside of healthcare settings may be a factor in spread.  CDC should work 
with public health authorities to ensure that such capacity exists.   
4. Demonstration projects:  CDC should work with local and state health departments to establish 
demonstration projects to:  
 Provide proof-of-concept for regional collaboratives in which actionable information from 
surveillance leads to targeted responses to effectively prevent transmission and spread of AR 
pathogens.  
 Test a variety of strategies to ensure maximal cost-effectiveness 
 Identify variability among potential sites to ensure that interventions are adaptable and scalable 
 Identify suitable metrics and outcome measures to ensure viability of such programs 
Activities to better monitor antimicrobial use and to continue to optimize antimicrobial prescribing in all 
healthcare settings 
The use of antimicrobial agents in ways that are not optimized for patient care has been a subject of 
concern since shortly after the introduction of penicillin.  A variety of factors, including a slowing in the 
development of new antimicrobials by the pharmaceutical industry (“the antibiotic pipeline”), an 
increase in the incidence of adverse consequences of antimicrobial use (especially C. difficile infection) 
and the excess expense incurred by non-optimal use of antimicrobials in an era of increasing fiscal 
constraints, have amplified this concern and increased the need for antimicrobial stewardship and 
judicious antimicrobial use in all healthcare settings.  To enhance the uptake and success of 
antimicrobial stewardship activities, CDC should consider augmenting efforts to: 
1. Obtain better data:  There is a need for better information on all aspects of antimicrobial use 
 Quantitatively linking antimicrobial use to resistance:  Studies conducted to date on limited 
populations (e.g., within a single hospital or other defined group) have not demonstrated a 
consistent and reproducible quantitative relationship between changes in antimicrobial use 
patterns and sustained changes in the bacterial resistance in that population.  Conducting larger 
scale, population-based intervention studies would be logistically challenging and likely resource 
intensive.  CDC should proactively assess the projected outcomes of such studies, the scientific 
validity of possible study designs, and the cost-benefits of such studies to determine whether 
such studies would be of value.  Alternatively, the utility and value of conducting ecological 
studies using data from large databases of antimicrobial prescribing and microbiology laboratory 
reports, which would be less costly but of more dubious scientific validity, should similarly be 
assessed.  Whether more quantitative models linking use and resistance can strengthen the case 
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for optimizing antimicrobial use based on a clear rationale of return on investment in 
stewardship will ultimately depend on the acceptability of the data used in the models.  
 Standardizing use measurement:  This is a long-standing problem that may be difficult to 
resolve, but any efforts to standardize the manner in which the volume or amount of use is 
characterized would help in measurement, particularly for international comparisons.  
 Prescribing patterns—inpatient and outpatient:  Interventions to optimize antimicrobial therapy 
could be more effectively designed with better data on the circumstances in which 
antimicrobials are prescribed, dispensed and used.  For human health, it would be helpful to 
know not just the relative amount of use in the outpatient and inpatient environments, but 
more specifically, which environments (doctors’ offices, clinics [including drug store clinics and 
other rapidly expanding settings], ambulatory surgery, etc.), who is prescribing (e.g., internists, 
surgeons, family practitioners, physician extenders [in jurisdictions where they have prescribing 
authority], etc.), what drugs are most commonly prescribed in which environments and settings 
and whether differences between prescribing, dispensing and consumption remain relatively 
constant or vary across settings or patient populations.  These are only some of the necessary 
data points that would greatly facilitate the development and implementation of successful 
interventions to ensure optimal antimicrobial use.   
 Better data on physician and consumer decision-making:  Significant strides have been made in 
growing awareness of the need for and benefits of improving the use of antimicrobials, both 
among prescribers and the public/consumers.  However, while educational campaigns are 
always necessary and beneficial, they may sometimes need to be augmented with targeted 
interventions to bring about the level of systemically significant change we’d optimally like to 
see.  Further advances in changing prescriber behavior would be aided by having more 
knowledge of the complexities and drivers of prescriber decision-making.  Studies designed and 
executed from the perspectives of behavioral science and economics are likely to be of 
considerable benefit in designing interventions.  
2. New communications initiatives (building on Get Smart):  The Get Smart program has been a 
tremendous success for CDC and has established a strong, internationally recognized brand.  The 
most recent Get Smart Week campaign (November 2011) was the most successful ever in terms of 
national (and international) media coverage and had significant impact in local media channels in a 
number of markets.  This argues strongly for continuing and expanding this successful program.   
This could be in the form of an extension of the brand using different channels or augmented 
content or could be an entirely new communication product as part of Get Smart.   
3. Promote the implementation of systems-thinking models:  The last 10 to 20 years has seen rapid 
growth in the application of business-model management systems to clinical medicine.  Although 
sometimes accompanied by unintended consequences, these systems—whether implemented for 
purely financial reasons, to address patient safety concerns, or for other reasons—have been used 
in some healthcare settings with measureable benefit quantified by epidemiologic studies, including 
case studies of hospital-based antimicrobial stewardship programs.   CDC should consider adapting 
and translating successful programs into transferable best practices and exploring the feasibility of 
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promoting such best practices to third-party payers as well as to non-hospital networks (e.g., dialysis 
centers).   
Promoting the development of new technologies for more rapid diagnostic testing for antimicrobial 
resistance, especially in clinical specimens  
The development and successful implementation of more rapid diagnostic testing for antimicrobial 
resistance, especially in clinical specimens, would be of great benefit in improving clinical outcomes and 
promoting antimicrobial stewardship.  Such tests could also be of great value in conducting trials of new 
antimicrobials by identifying eligible patients more efficiently, thus reducing the number of study 
subjects needed for initial enrollment, decreasing both the cost and time required to conduct such 
studies.  This could serve to help restock the antibiotic pipeline with new drugs.  CDC should work with 
public sector and private sector partners to help answer the following questions: 
1. What is the optimum role for CDC to play in research, development, testing and diffusion 
of new, rapid diagnostic testing for antimicrobial resistance?  
2. Can point of care (POC) testing for AR in clinical specimens be realized in the next five 
years based on existing technology? 
3. If POC testing for AR in clinical specimens is not a realistic goal in the near future, what is 
maximally achievable in reducing the time from specimen collection to identification of 
AR in an infecting microorganism? 
4. Can the benefits of rapid diagnostic testing in terms of better patient outcomes (as well 
as for stewardship and cost savings) be calculated for various time-frames?  That is, what 
is “good enough”—do we need testing at the point of care or is six hours, or 12 hours 
adequately beneficial to achieve better outcomes?   This information could help 
determine proposed levels of investment in developing and deploying new technology.   
 
Disease burden assessment 
 Support for public health interventions generally, and infection control activities in particular, have 
sometimes been hampered by methodological difficulties in demonstrating their economic value as a 
return on investment by health care institutions and/or by a perception among some observers that 
such efforts are not fiscally cost-effective.     In recent years, combinations of epidemiologic and 
econometric analyses have helped to demonstrate clearly the positive return on investment that may 
accrue from a variety of public health interventions, including healthcare-associated infection 
prevention and control.  Augmenting the capacity to do such studies specifically for demonstrating the 
ROI of preventing the spread of antimicrobial resistance and preventing AR infections would greatly 
increase the awareness of the benefit of AR prevention and control activities.  
5. Integrated burden assessment is more likely to lead to integrated prevention capacity:  
Many current economic analyses of AR problems are done for specific microorganisms 
(e.g., MRSA, S. pneumoniae) or for specific settings (e.g., acute care hospitals).  This may 
significantly understate the actual burden of AR for which basic prevention approaches 
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(i.e., use antimicrobials wisely, detect early and control rapidly the emergence of new 
resistance, and interrupt transmission of known resistant problems) are similar 
regardless of microorganism or setting.  CDC should explore methods for more accurately 
estimating the burden of antimicrobial resistance across the most impactful pathogens 
and across all settings.  This could significantly enhance support for prevention activities 
at community, state and national levels.   
6. More quantitative assessment of prevention effectiveness (PE) and return on financial 
investment (ROI):  Similarly, CDC should apply to AR the increasingly sophisticated 
methods developed for measuring PE and ROI for other public health problems in the 
community and in healthcare settings.  
7. Better quantification and description of the problem will permit more effective 
communication and likely lead to increased motivation for prevention.  CDC should 
incorporate data on disease burden attributable to AR in communication efforts, 
including prevention campaigns and antimicrobial stewardship campaigns aimed at 
healthcare professionals, providers, payers, consumers and decision-makers.  
 
 
Strategic Questions   
In addition to the five Strategic Priorities, the consultants raised five questions bearing on strategy 
formulation and implementation that were recommended for consideration by CDC.  These questions 
emerged as themes during discussions during the meeting and, in general, addressed how CDC wished 
to define its role in various aspects of its public health work on preventing antimicrobial resistant 
infections.    These questions were prompted by, and in response to, the charge to the consultants 
containing the proposed criteria for assessing priorities (see appendix 1, page 2 and page 6).   
These questions were:  
1. Antimicrobial use in agriculture:  Responsibility for regulation and oversight is the purview of FDA 
and USDA; CDC’s role is primarily limited to issues surrounding human health.  How does CDC work 
with other Federal agencies to address this public health concern and what role, if any, could/should 
CDC have in changing practices with regard to antimicrobial use in agricultural settings? 
2. Research and development (R & D) of new diagnostic tests: R & D traditionally is the role of the 
private sector and/or NIH-funded extramural work, primarily in academic institutions.  What can 
CDC contribute to encouraging, hastening, facilitating, deploying, and/or creating standards of 
practice for the use of new and more rapid diagnostic tests for AR?  
3. Innovation vs. maintenance of ongoing activities:  As in all areas of public health, CDC has been a 
leader and innovator for many years in developing programs to monitor, prevent and control 
antimicrobial resistance.  Population-based surveillance of targeted microorganisms through the 
Emerging Infections Program, educational campaigns to improve antimicrobial use under the Get 
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Smart programs, and support for prevention collaboratives have all demonstrated extraordinary 
success and have enabled significant improvements in public health.   Given increasingly limited 
sources of funding, the resource needs of maintaining such established, valuable programs is in 
competition with the resources needed to develop the next generation of innovative, cutting edge 
programs to address the ever changing challenges of antimicrobial resistance.  To what extent could 
CDC explore options for out-sourcing, handing off established programs extramurally and/or 
redirecting current program emphases to encourage further innovation, proof-of-concept 
exploratory projects, and new program development and evaluation? 
4. Clinical guideline development:  Is this an optimal CDC function or should this be the purview of 
professional organizations?  Does the CDC imprimatur carry such weight as to justify a greater level 
of CDC involvement?  
5. Data for clinical decision-making:  To what extent could CDC better present its surveillance data to 
assist clinical decision-making, especially with regard to empiric antimicrobial therapy based on local 
resistance patterns? 
 
Next Steps: How this report will be used 
 
When final, the workshop report will be posted on the CDC AR website.  The final report will be one of 
several inputs to the newly-formed Antimicrobial Resistance Working Group of CDC’s Office of Infectious 
Diseases Board of Scientific Counselors.  The final report will also serve as a core document for further 
development of CDC’s Strategic Plan for Combating Antimicrobial Resistance.  In addition, the final 
report and the CDC Strategic Plan that follows will help guide CDC’s submissions to the 2012 and 2013 
updates of the Federal Action Plan for Combating Antimicrobial Resistance of the Interagency Task Force 
on Antimicrobial Resistance 
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The purpose of this meeting is to gather a diverse set of opinions from experts in clinical and 
laboratory medicine and public health to assist CDC in making decisions on how best to 
prioritize our work in the area of prevention and control of antimicrobial-resistant infections.  
Each consultant is encouraged to speak from her or his professional perspective taking into 
account CDC’s responsibility to address national public health goals.  There is no attempt to 
develop a consensus view or make a group recommendation.   
 
CDC will continue to align its strategic priorities with the content of A Public Health Action Plan 
to Combat Antimicrobial Resistance (http://www.cdc.gov/drugresistance/pdf/public-health-
action-plan-combat-antimicrobial-resistance.pdf).  This Federal Action Plan, which is now 
revised and updated annually, lays out key goals and actions to which federal departments and 
agencies are committed in the areas of surveillance, prevention and control, research, and 
product development. While CDC has important roles in all of these areas, CDC is the 
coordinator for many of the actions in the sections on surveillance and prevention and control. 
Because the science and the public health imperatives in these areas continue to evolve rapidly, 
we wish to ensure that CDC’s activities are maximally effective and fully integrated into the 
overall federal effort and the broad array of initiatives being carried out in the public health and 
clinical communities.  Thus, we are seeking opinions and feedback from a selected group of 
consultants on potential strategic priorities and specific projects and activities that CDC might 
pursue during the next three years to fulfill its role in the Federal Action Plan. 
 
Workshop Structure:  
 
CDC Activities 
For those action items in the Action Plan for which CDC is the coordinator, CDC is considering a 
variety of possible strategies as well as specific activities to ensure that the goals are achieved 
in the most effective manner, particularly in this time of global economic austerity. Through 
presentations by CDC staff on the first morning of the workshop, participants will be provided 
with overviews of these possible strategies and will be asked, during breakout sessions, to 
provide their individual insights and opinions on which activities may be most successful based 
on the following criteria:  
 Disease burden prevented:  Activities which could prevent the most morbidity, mortality, and 
economic cost  
 Feasibility:  Activities which are most likely to show measurable progress within a three year 
timeframe starting in 2013   
 Scope of CDC influence:  Activities for which CDC actions can have the most direct 
influence on prevention of AR diseases/infections  
 Innovation:  Activities which are innovative and offer new approaches to addressing existing 
or emerging problems. 
 Opportunities for prevention:   
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o Activities which fill gaps in prevention by addressing missed opportunities to implement 
known prevention strategies, especially if these prevention strategies are highly cost-
effective (positive return on investment [ROI]) 
o Activities which fill gaps in prevention by developing prevention strategies where 
effective strategies are not known or proven 
o Activities which fill gaps in prevention by working in critical areas where other 
groups/agencies/organizations are not currently active 
  
Consultants will be asked to select a set of activities which they feel may have the highest 
priority for consideration by CDC in program and project planning during the next three years. 
 
Partner Activities 
We are also interested in hearing about activities in which consultants are currently engaged or 
which they plan to start within the next 12 to 24 months that could involve CDC as a valued 
collaborator.  Participants are invited to discuss these ideas with a particular emphasis on what 
CDC’s role as a collaborator might be.   
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FAQs 
 Antimicrobial Resistance (AR) is a global public health crisis that encompasses a wide range of 
microorganisms.  Why are we not explicitly discussing international activities?  Why is the 
discussion limited to bacterial and fungal AR?   
 
Because of the breadth and complexity of the topic of antimicrobial resistance, we have limited 
the focus of this particular workshop to domestic priorities in the United States that address 
bacterial and fungal infections.   A two-day workshop is insufficient to address the global burden 
of all AR pathogens.   
 
We recognize that antimicrobial resistance is a global problem and that resistance problems 
complicating the treatment of viral, parasitic and mycobacterial infections around the world takes 
a toll in human life and suffering so extensive that international surveillance systems struggle to 
quantify it.  We will apply the insights we gain during this workshop to the design of future 
engagements with international partners so that we can, in the near future, assemble a truly 
global agenda for CDC’s scientific and programmatic collaborations with partners both in the 
United States and around the world.    
 
 Will the results of this workshop drive all CDC activities in antimicrobial resistance? 
 
No.  Each CDC Center and Division needs to be able to prioritize its own activities within the 
context of the specialized needs of the public’s health as it pertains to that Division’s area of 
focus. The CDC Office of Antimicrobial Resistance coordinates across CDC Divisions and 
Centers and supports specific activities which promote an agency-wide perspective.  The results 
of this workshop will be a critical part of the process by which CDC develops and promotes its 
broad-based agency goals for AR; these goals are complementary to, and in no way replace or 
compete with the disease-specific goals and objectives of CDC Divisions and Centers.   
 
 Will there be other opportunities for input? 
 
Yes, many and with some frequency.  We just held the public meeting of the Interagency Task 
Force for Antimicrobial Resistance on November 15, 2011 and such meetings will be held 
annually.  The Board of Scientific Counselors of the Office of Infectious Diseases at CDC is 
forming a Working Group on Antimicrobial Resistance.  Meetings of the Board of Scientific 
Counselors are public meetings and are announced in the Federal Register (as are the public 
meetings of the Interagency Task Force).  In addition to these formal venues, CDC will be 
continuing active engagement with partners and constituents in a structured way.  Some 
possible avenues for this engagement will be discussed during the workshop.    
 
 What kind of follow-up can we expect from this meeting? 
 
Attendees will be given a chance to review and comment on the workshop report CDC.  We are 
also eager to hear from you about ideas you may have for how to promote increased interaction 
with CDC regarding AR.  Those attendees who wish can sign up for email updates when new 
material is posted on the CDC website on antimicrobial resistance.  
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Day 1--Tuesday, December 6, 2011 
7:30 AM Participant Registration 
8:30 AM Convene Meeting 
8:35 AM Welcome on Behalf of CDC and Opening Remarks: The importance of 
preventing AR infections to public health and CDC’s role 
8:45 AM Overview and Goals of the Meeting 
Meeting Logistics 
9:00 AM Panel 1: CDC Surveillance for AR: Status and Future Directions 
10:00 AM Break 
10:30 AM Panel 2: CDC Activities for Improving Antimicrobial Use: Status and Future 
Directions 
11:30 AM Panel 3: CDC Initiatives to Prevent Infection and the Spread of AR Pathogens 
—Translating Science into Program: Status and Future Directions 
12:30 PM Working Lunch 
1:30 PM Breakout Session I: AR surveillance: discussion of CDC’s proposed future 
directions  
2:45 PM Break 
3:30 PM Breakout Session II: Improving antimicrobial use: discussion of CDC’s 
proposed future directions 
4:45 PM Day 1 Wrap-up 
5:15 PM Adjourn 
6:30 PM Dinner (optional) 
Day 2--Wednesday, December 7, 2011 
8:30 AM Review of Day 1 and Introduction to Day 2 
9:00 AM Breakout Session III: Preventing infections and spread of AR pathogens —
translating science into program: discussion of CDC’s proposed future 
directions 
10:15 AM Break 
11:00 AM Report from Breakout Session I, Groups A - D 
11:30 AM  Report from Breakout Session II, Groups A - D 
12 Noon Lunch 
1:00 PM  Report from Breakout Session III, Groups A -D 
1:30 PM Report from Enteric Diseases Breakout Sessions, Group E 
2:00 PM Panel and Discussion: Next Steps 
3:00  PM Meeting Summary and Follow-up Plans 
3:30 PM Adjourn 
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Breakout Sessions Overview 
BREAKOUT SESSION GOALS 
 To obtain consultants’ input into CDC’s consideration of priorities for antimicrobial resistance (AR) 
activities currently listed in A Public Health Action Plan to Combat Antimicrobial Resistance (Action 
Plan) (http://www.cdc.gov/drugresistance/pdf/public-health-action-plan-combat-antimicrobial-
resistance.pdf) and which are continuing into 2013 and beyond 
 To obtain consultants’ input into CDC’s consideration of priorities for AR activities for submission to 
next year’s update of the Action Plan  
 To identify partner AR activities in which CDC could be a collaborator 
 
HOW THE BREAKOUT SESSIONS WILL WORK 
There are three breakout sessions: 
 Surveillance and Monitoring—Tuesday, Dec. 6, 1:30 – 2:45 PM 
 Improving Antimicrobial Use—Tuesday, Dec. 6, 3:30 – 4:45 PM 
 Translating science into program: Preventing infections and spread of AR pathogens—Wednesday, 
Dec. 7, 9 – 10:15 AM 
 
During each breakout session, there will be five breakout groups, Groups A, B, C, D and E (see Table 1).   
 Groups A, B, C and D, will each review the same materials and seek the consultants’ input on relative 
priorities for CDC activities to go in the next version of the Federal AR Action Plan. (Breakout Session 
Guide, below).    
 Group E, which is hosted by the Division of Foodborne, Waterborne and Enteric Diseases, will 
consider CDC’s collaborations and role in current and potential Federal AR Action Plan activities 
related to AR in enteric bacteria.   For more information on these sessions, please contact Dr. Beth 
Karp, Office#: 404-639-5097, bkarp@cdc.gov 
Table 1 
 Tuesday, Dec. 6 Tuesday, Dec. 6 Wednesday, Dec. 7 
 1:30 – 2:45 PM 3:30 – 4:45 PM 9 – 10:15 AM 
 Surveillance and monitoring Improving Antimicrobial Use Translating science into 
program: Preventing 
infections and spread of AR 
pathogen 
Group A Action Plan priorities Action Plan priorities Action Plan priorities 
Group B Action Plan priorities Action Plan priorities Action Plan priorities 
Group C Action Plan priorities Action Plan priorities Action Plan priorities 
Group D Action Plan priorities Action Plan priorities Action Plan priorities 
Group E CDC role and collaboration in 
enteric diseases 
CDC role and collaboration in 
enteric diseases 
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Breakout Sessions Guide for Consultants, Groups A - D 
 
 In each of the three breakout sessions—surveillance, antimicrobial use, and prevention, 
consultants will be provided with a list that includes:   
 Current CDC activities that are related to specific actions in the Federal AR Action Plan 
and that will be continuing into 2013 
 New and enhanced CDC activities that could be added to the Federal AR Action Plan for 
implementation in 2013 or beyond 
 
 Looking at this list of current CDC activities continuing into 2013 and CDC activities that could be 
added starting in 2013, participants will be asked to review, discuss and provide their 
perspectives on the relative priority of these activities.  Each activity will be assigned to one of 
three categories: 
 Highest priority – Has the greatest impact on public health by preventing AR infections and 
improving patient outcomes  
 High priority—Is valuable for public health by preventing AR infections and improving 
patient outcomes  
 Priority—Contributes to public health by preventing AR infections and improving patient 
outcomes  
 
 Prioritization should take into account a national public health perspective and be based on the 
following criteria: 
 Disease burden prevented:  Activities which could prevent the most morbidity, mortality 
and economic cost  
 Feasibility:  Activities which are most likely to show measurable progress within a three year 
timeframe starting in 2013.   
 Scope of CDC influence:  Activities for which CDC actions can have the most direct influence 
on prevention of AR diseases/infections  
 Innovation:  Activities which are innovative and offer new approaches to addressing existing 
or emerging problems. 
 Opportunities for prevention:   
 Activities which fill gaps in prevention by addressing missed opportunities to implement 
known prevention strategies, especially if these prevention strategies have are highly 
cost-effective (positive return on investment [ROI]) 
 Activities which fill gaps in prevention by developing prevention strategies where 
effective strategies are not known or proven 
 Activities which fill gaps in prevention by working in critical areas where other 
groups/agencies/organizations are not currently active 
 
 Following this prioritization, activities suggested by partners with which CDC could be invited to 
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BREAKOUT GROUP PROCESS GROUPS A - D—STEP BY STEP  
 
1. The Facilitator will ask the group members to introduce themselves and will briefly review the 
breakout group goals and process.    
2. The Facilitator will ask the group to identify a consultant to accompany the recorder and represent 
the group in the summary meeting at the end of the session to prepare the breakout group report 
(see step 9). 
3. Consultants will then have a few minutes to review the CDC activities under discussion (using the 
Activities Selection Form for that session) and ask questions of the CDC staff in the group.   
 All group members should complete the Feedback Form for that particular session making 
comments as desired relating to the discussion.   
4. To initiate the prioritization process, consultants will then be invited to highlight three activities 
from the Activities Selection Form which they feel might be particularly important for achieving the 
public health goal of reducing the disease burden of antimicrobial resistant infections. The recorder 
will tally consultants’ selections on the posters displayed in each room.   
5. After additional discussion, consultants will then be asked to categorize each of the activities into 
one of three groups:   
 Highest priority – Has the greatest impact on public health by preventing AR infections and 
improving patient outcomes  
 High priority—Is valuable for public health by preventing AR infections and improving patient 
outcomes  
 Priority—Contributes to public health by preventing AR infections and improving patient 
outcomes  
6. Consultants’ selections will be tallied on a set of pre-printed posters (2.5’ by 2.0’) in each room.   
Consultants can place colored dots directly on the posters representing highest priority (red), high 
priority (yellow), and priority (green). 
7. All group members will have an opportunity to review and comment on the consultants’ selections.   
8. Then, consultants will be invited to suggest activities which they or their organizations are currently 
conducting or plan to conduct and in which CDC could be invited to collaborate.   These will be listed 
by the Recorder on the on the posters.   
9. At the end of the session, the facilitator and recorder will collect the Feedback Forms from each 
group member.  
10. Following the end of each session, there will be a break during which the Recorder and the 
consultant representing the each of the groups will meet, share the results of their sessions and 
prepare for the 30 minute breakout group report which will occur between 11 AM and 2 PM on the 
second day of the workshop.  At this summary meeting, we’d like the consultants to identify one 
consultant who will volunteer to present the combined report for all four breakout groups.    
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The purpose of the project prioritization exercise was to gather opinions from each of the expert 
consultants on their views of the relative priority of current and proposed CDC activities included 
in A Public Health Action Plan to Combat Antimicrobial Resistance. 
 
The process is described in detail in Appendix 1.  Briefly, there were three breakout sessions—
one each focusing on surveillance, antimicrobial use, and prevention & control measure.  During 
each session, consultants were divided into four groups led by a CDC facilitator.  Consultants 
were provided with lists of current CDC activities that are described as specific activities or 
projects in the Federal AR Action Plan and that will be continuing into 2013, as well as new and 
enhanced CDC activities or projects that could be added to the Federal AR Action Plan for 
implementation in 2013 or beyond.  Following a discussion period, consultants were asked to 
provide their individual views on the relative priority of those activities for addressing the 
problem of antimicrobial resistance in regard to CDC’s mission to improve the public’s health.  
Consultants were asked to divide the activities into three priority groups: highest priority, high 
priority and priority.  The consultants’ individual assessments were then reviewed and analyzed.   
 
Caveats to analysis and interpretation 
Although the discussions were facilitated and followed a similar structure, there was 
considerable latitude given to the groups in how they approached the tasks.  For this and other 
operational reasons, although numerical rankings can be (and were) computed from the 
information obtained during the breakout sessions, a qualitative  analysis appeared to be more 
valuable than a strictly quantitative one for guiding CDC’s decision-making going forward.  A 
review of all the information provided by consultants, including reviews of comment sheets, 
recorders’ notes, and notes from the debrief meetings held after each session, indicated some 
clear patterns which were consistent with the numerical analysis.  
 
General conclusions 
In all three breakout sessions—Surveillance, Antimicrobial Use, Prevention and Control—
consultants generally tended to favor activities that: 
 Broader in focus—that looked at applicability across a range of pathogens, diseases, 
syndromes, care settings, patient populations, etc. 
 Took a national perspective—activities that themselves had a national scope or were 
scalable to a national scope  
 Provided actionable guidance to clinicians and public health officials 
 Encouraged networking and accountability 
 Were quantitative and provided data that were relevant for prioritization and decision-making  
 
Qualifications on interpretation 
 Only rarely did consultants feel any project did not have some valuable or importance 
 Comments indicated that discussions generally did adhere to the criteria provided for 
prioritizing (i.e., most impactful, most practical, CDC filling a gap, etc.) 
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 Some prioritization decisions related to opinions about the relevance of CDC’s role in an 
activity, rather than the intrinsic value of the activity itself; specifically whether an activity 
could be better or as well conducted elsewhere in government or in by a non-governmental 
organization 
 
Specific results  
Surveillance—the activities that tended to be rated highly by individual consultants were often 
related to the idea of enhancing a national (and eventually international) surveillance network 
which has the following characteristics:  
 Incorporates various pathogens of concern independent of location of colonization or 
infection or route or transmission 
 Promotes electronic data capture and reporting 
 Provides regular reports of national scope with enhanced regional/state capacity to identify 
“hot spots” or geographic foci of problems 
 Provides for interoperable data systems and translation to consistent denominators 
 Is population-based 
Antimicrobial use-- the activities that tended to be rated highly by individual consultants often 
stressed the importance of: 
 Working on identifying and promoting known “best practices” to improve antibiotic use. 
 Working collaboratively with professional organizations and regulatory and accreditation 
agencies to develop quality measures and enhance compliance with measures to improve 
antibiotic use. 
 Getting better data on prescribing—the “who, what, when and where”  regarding  
antimicrobial prescribing, prescription fulfillment and consumption 
 Getting better information on prescribers’ knowledge, attitudes and behaviors and what 
“triggers” or “levers” could best influence that behavior (and the same for consumers). 
 Getting better data on accountability and outcome measurement for prescribers and clinical 
results (i.e., can we prove that improved prescribing performance [however measured] leads 
to better, or at least equally good, patient outcomes as well as improvement in resistance 
“ecology”) 
Prevention and control-- the activities that tended to be rated highly by individual consultants fell 
into three general categories: 
 Better and more rapid diagnostic tests for identification and resistance (preferably POC 
testing at the bedside or in the  doctor’s office 
 Vaccines to prevent infections with resistant pathogens 
 Developing state-based or regional collaborative efforts to address resistance problems 
across care settings with process and outcome evaluation, systems thinking, local 
surveillance benchmarked against national rates and structured interaction between public 
health and clinical professionals 
     
 
 




During each of the breakout groups, consultants were invited to suggest additional projects, not listed 
on the handouts, in which CDC could partner with other agencies or organizations or build on existing 
projects to fill gaps in the public health portfolio for AR prevention.  Similar ideas were expressed in 
more than one group and are categorized below. 
Surveillance of Antimicrobial Resistant (AR) Pathogens 
1. Projects to enhance surveillance of foodborne AR pathogens 
a. Look for synergies between ABCs and NARMS data and methods 
b. Synthesize the three NARMS report for better correlation between animal and human 
isolates 
c. Build on NARMS data and methods to further epidemiologic knowledge on transmission of 
resistance of pathogens (MRSA, C. diff) not currently tracked in NARMS from meat and 
other agricultural sources  
2. Projects to enhance usefulness of CDC AR surveillance data  
a. Develop communications strategies for various audiences 
b. Publish an annual or biannual national AR report  
c. Make surveillance data available in raw form to allow for interactive web-based access to 
these data for additional analysis as well as data dissemination and analysis (as is currently 
done with ILI surveillance) 
3. Projects to enhance the accuracy and completeness of CDC AR surveillance data  
a. Standardize MDR definitions and nomenclature 
b. Promote better diagnostics to increase capacity to identify AR organisms more rapidly and 
more completely 
4. Projects to enhance epidemiologic knowledge of AR in patients 
a. Studies correlating surveillance data on specific patterns of resistance in blood culture 
isolates with patient setting, antimicrobial exposure and treatment and patient outcomes.   
b. Studies of healthcare workers in a variety of settings (e.g., acute care, LTC, hemodialysis) 
with regard to incidence and prevalence of AR resistance in colonized HCWs, transmission to 
and from patients (possibly including family based transmission)  
c. Studies to more completely characterize populations at highest risk for colonization and 
infection with multiply resistant gram-negatives  
Antimicrobial Use 
1. Projects to enhance surveillance of antimicrobial use (AU) 
a. Continue periodic point prevalence surveys of inpatient AU 
b. Accelerate data availability from the NHSN AU option  
c. Expand AU surveillance (and interventions) to long-term care (LTC) and long-term acute care 
(LTAC)  
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d. Expand the use of Veterans Affairs Health System data which is already available in electronic 
form 
e. Studies to correlate longitudinal patterns of use in both inpatient and outpatient settings with 
resistance patterns of isolates from patients  
f. Studies to correlate longitudinal patterns of use in patients with resistance patterns of isolates 
from patients in different geographical locations 
g. Increase scope of AU surveillance to include national distribution and volume of AU in humans, 
animals, agriculture—analyzed by geographic area, by setting, and other demographic and 
operational variables correlated with resistance 
h. Encourage data sharing about antimicrobial use from individual pharmacies and facilities all the 
way up to the national/global scale. (Researchers are blocked from getting use data other than 
from their own facility.)   
i. Surveillance should include measures of inappropriate use 
2. Projects to develop, test, evaluate, implement and disseminate Intervention strategies to improve 
AU 
a. Develop a “driver diagram” to include as part of the AU change package for use by facilities and 
practices 
b. Studies to better describe KAB of both inpatient and outpatient prescribers to help focus and 
target interventions  
c. Address concerns (medico-legal and others) about risk to prescribers of a bad patient outcomes 
after using “best therapy” or “guideline adherent” therapy rather than “maximal therapy”, i.e., 
will prescriber face consequences for not using “heaviest guns” for treatment in case of a bad 
outcomes, even if unavoidable.   
d. Expand studies to include evaluation in various settings of the broadest range of interventions 
for changing prescriber behavior—financial incentives, institutional and professional culture, 
marketing, etc.  
e. Explore use of surrogate markers and biomarkers for infections, especially in the ICU, to improve 
choices for empiric therapy 
f. Develop specific guidelines for patients with pan-resistant infections 
g. Work with accreditors and others (HEDIS, JCAHO, CMS) to develop inpatient and outpatient 
quality measures that can be used as benchmarks for prescriber behavior 
h. Enhance communication efforts to stress accountability of prescribers and dispensers for AR 
problems due to inappropriate AU 
i. Work with partner agencies in their efforts to develop or update educational materials on the 
judicious use of antimicrobial agents in food animals and make those materials available to 
veterinarians, veterinary students and food animal producers 
j. Promote/conduct clinical trials to determine the appropriate duration of therapy 
Prevention & Control   
1. Infection Control  (IC) Projects 
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a. Work with WHO and other international organizations to promote infection prevention and 
control for AR in all settings globally  
b. More clearly define those MDROs that should be subject to special IC attention, especially in 
LTC and acute care settings that share patients  
2. Public Health System Projects 
a. Study the usefulness and impact of mandatory reporting of AR in LTC settings 
b. Fill gaps in knowledge for established infection prevention guidelines 
3. Laboratory Projects 
a. More fully define what role CDC will play in development of rapid diagnostic tests for AR in 
the laboratory 
b. Enhance CDC’s role in the long-term development of point of care diagnostic testing for AR  
c. Explore ways of using CDC surveillance data paired with information on patient outcomes 
and antimicrobial treatments to assess the correlation between antimicrobial susceptibility 
testing (AST) data and treatment outcomes, for the purpose of updating or altering AST 
procedures/methods as necessary   
d. Studies to correlate AST data and reporting of those data in clinical settings with AU and 
transmission of AR pathogens   
4. Other Projects 
a. More fully define what role CDC will play in development of candidate vaccines for AR 
pathogens 
b. CDC should establish training grants for AR research and prevention, both for individual 
investigators and at the institutional level to increase the pipeline of trained researchers and 
experts in the field  
 
 
 
